News
Phase 1 trial of in vivo CAR-T therapy for relapsed AML registered in Beijing
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A study registered on ClinicalTrials.gov on 25 September 2026 plans to test an in vivo CAR-T therapy targeting CLL-1 in up to 12 adults with relapsed or refractory acute myeloid leukaemia at the Chinese PLA General Hospital in Beijing. The record describes a single-arm phase 1 dose-escalation design, lists an estimated start date of 30 September 2026, and shows the status as not yet recruiting.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open access / public domain; summary and link published here, the original remains authoritative.